Walleye Capital LLC Takes $6.44 Million Position in CG Oncology, Inc. (NASDAQ:CGON)

Walleye Capital LLC purchased a new position in CG Oncology, Inc. (NASDAQ:CGON) in the fourth quarter, Holdings Channel.com reports. The fund purchased 224,580 shares of the company’s stock, valued at approximately $6,441,000.

Several other large investors have also added to or reduced their stakes in CGON. Vanguard Group Inc. lifted its position in shares of CG Oncology by 15.3% in the 4th quarter. Vanguard Group Inc. now owns 5,861,082 shares of the company’s stock worth $168,096,000 after purchasing an additional 779,730 shares during the period. Wellington Management Group LLP lifted its holdings in CG Oncology by 274.4% in the fourth quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company’s stock worth $54,792,000 after buying an additional 1,400,251 shares during the period. Alliancebernstein L.P. boosted its position in CG Oncology by 61.6% during the 4th quarter. Alliancebernstein L.P. now owns 1,817,887 shares of the company’s stock valued at $52,137,000 after acquiring an additional 692,982 shares in the last quarter. State Street Corp grew its holdings in shares of CG Oncology by 73.0% during the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company’s stock worth $64,166,000 after acquiring an additional 717,722 shares during the period. Finally, Franklin Resources Inc. grew its stake in CG Oncology by 3.7% in the fourth quarter. Franklin Resources Inc. now owns 1,275,891 shares of the company’s stock worth $36,593,000 after purchasing an additional 45,698 shares during the period. Institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Up 0.2 %

Shares of NASDAQ CGON opened at $20.11 on Wednesday. The firm has a market cap of $1.53 billion, a P/E ratio of -14.16 and a beta of 1.24. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $46.99. The company has a 50 day moving average of $24.79 and a 200 day moving average of $30.11.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Tuesday, March 25th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.11). The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. As a group, equities analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on CGON shares. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a research note on Monday, March 31st. TD Cowen started coverage on shares of CG Oncology in a report on Tuesday, January 7th. They set a “buy” rating for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $63.88.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.